From the Advisory Board
By Justin M. Watts, MD; Peter Maslak, MD; Martin S. Tallman, MD A 47-year-old woman presented for evaluation of pancytopenia. She had been diagnosed with papillary thyroid cancer 18 months earlier and underwent total thyroidectomy followed by radioiodine (I-131) ablation for nodal and small pulmonary metastases. Cumulative dose of radioactive iodine was 312 mCi. She…
By Barbara Ann Burtness, MD A 52-year-old man who lives in the Midwest presents with a lesion in his nose. He has an extensive history of sun exposure and a 35 pack-year smoking history. The patient sought attention from an otolaryngologist, who cultured the lesion in the right upper medial nasal vestibule but noted “no…
This article reviews the current evidence for the role of aromatase inhibitors (AIs) in the treatment of advanced stage or recurrent endometrial cancer.
Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.
Isabel Cunningham, MD, Cancer Therapy Advisor Advisory Board member, weighs in on recent discoveries in the treatment of hematologic cancers.
A case report that looks into a breast cancer survivor experiencing sex-related headaches after treatment.
Steven J. Cohen, MD, CTA Advisory Board member highlights key science from the 2015 Gastrointestinal Cancer Symposium.
Leukemia is sometimes a solid, metastatic, and invasive neoplasm, but this is forgotten when leukemia is viewed as only a “liquid” cancer.
CTA Advisory Board member, Neal Shore, MD, puts CHAARTED trial results into context.
CTA Board Member Steven Cohen, MD, discusses exciting advances regarding treatment options for metastatic pancreatic cancer.
The Eastern Cooperative Oncology Group (ECOG) conducted a trial to investigate whether treatment deintensification was feasible in patients with HPV-associated cancer.
Neal D. Shore, MD, FACS, sits down with CTA to discuss PROSTVAC as a targeted immunotherapy for prostate cancer.
Dr. Jeffrey Farma provides his insight on treating the elderly patient population in the surgical oncology setting.
Oncologists who care for non-small cell lung cancer (NSCLC) patients need to develop management strategies.
Immune therapies hold substantial promise to improve therapeutic options for patients with metastatic renal cancer.
Dr. Dizon and patient advocate Katherine O’Brien discuss the difficulty of communicating cancer and give advice on common miscommunications.
Dr. Burtness, a member of the Cancer Therapy Advisory Board, reflects on the loss of Dr. Abraham Borbor, the only certified internist in Liberia who recently died of Ebola.
Mario Sznol, MD, comments on the results of his phase 1 study reporting on data from patients with metastatic melanoma treated with nivolumab.
FDA approval of ramucirumab offers a new therapy option for patients with gastric cancer, which is notoriously aggressive and difficult disease to treat.
Editorial Board Member Don Dizon, MD, answers some questions about issues in breast cancer treatment today.